title: [Antiangiogenic therapy at the ocular surface: when, what and why?].
abstract: There are numerous indications for local antiangiogenic therapy at the ocular surface. These include vision-limiting corneal neovascularization, corneal blood and lymphatic vessels endangering corneal graft survival and tumor-associated lymphangiogenesis. A literature review in PubMed and own clinical and experimental data form the basis for a discussion of the indications, current therapeutic options and potential side-effects of local antiangiogenic therapy at the ocular surface.
authors.affiliation: Augenklinik mit Poliklinik, Labor für Okuläre Angiogenese, Lymphangiogenese und Transplantatimmunologie, Universität Erlangen-Nürnberg, Universitäts-Augenklinik Erlangen, Schwabachanlage 6, 91054, Erlangen, Deutschland.
authors.forename: F
authors.initials: F
authors.lastname: Bock
authors.forename: B
authors.initials: B
authors.lastname: Regenfuss
authors.forename: C
authors.initials: C
authors.lastname: Cursiefen
mesh_terms: D020533:Angiogenesis Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D003228:Conjunctiva / Q000098:blood supply* / Q000187:drug effects; D003230:Conjunctival Neoplasms / Q000188:drug therapy*; D016510:Corneal Neovascularization / Q000188:drug therapy* / Q000209:etiology; D016039:Corneal Transplantation; D015812:Glaucoma, Angle-Closure / Q000601:surgery*; D006085:Graft Survival / Q000187:drug effects; D006801:Humans; D042583:Lymphangiogenesis / Q000187:drug effects; D008207:Lymphatic Metastasis / Q000517:prevention & control; D008545:Melanoma / Q000188:drug therapy*; D011183:Postoperative Complications / Q000188:drug therapy*; D011625:Pterygium / Q000188:drug therapy*; D014792:Visual Acuity / Q000187:drug effects*
chemical_list: D020533:Angiogenesis Inhibitors